Stock Analiz

Bone Biologics Corp BBLG

Industrial Specialties · data as of November 13, 2026

$0.33Market cap $1M
Open the interactive analysis →

Bone Biologics Corp (BBLG) is a healthcare company listed in the US with a market value of about $1M.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a 5-year average ROIC of -92%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 40798% above the current price.

About Bone Biologics

Bone Biologics is listed in the US and classified in industrial specialties. It was profitable in 0 of the last 9 years in our data. Its share count rose by 14686% over three years (dilution for shareholders).

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+40798%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-92.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal year202520242023202220212020201920182017
Revenue—————$1.1B$1.1B——
Net income-$3M-$4M-$9M-$1M-$2M-$2M-$3M-$4M-$7M
Free cash flow—————————
EPS (diluted)$-2.65$-28.96$-203.99$-186.84$-2.10$-3.78$-2.82$-5.28$-10.86
Net margin—————-0.2%-0.3%——
ROIC-47.5%-95.7%-256.3%-48.7%-13.2%——-548.7%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Bone Biologics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 40798% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Bone Biologics pay a dividend?

Not currently.

Is Bone Biologics a good stock to buy?

We do not give buy or sell advice. Bone Biologics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.